Novartis Pharmaceuticals UK LimitedUK Head OfficeFrimley Business Park FrimleyCamberley Surrey GU16 7SR
+44 1276 692255+44 1276 692508Monday - Friday,8:30 - 17:30
Novartis International AGInvestor RelationsP.O. BoxCH-4002 BaselSwitzerland
+41 61 324 79 firstname.lastname@example.org
Novartis UK Press OfficePress Office enquiries only
+44 1276 email@example.com
Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.
For enquiries contact
+44 1276 698 firstname.lastname@example.org
Did you know that Novartis UK funds 10% of pharmaceutical industry sponsored phase II-IV clinical trials? Or that Alcon is the UK's number one contact lens company? Find out more about who we are, what we do and why we do it, here, in our new Corporate Brochure.
23 Nov 2015
Novartis announced today that the European Commission (EC) has granted authorisation for Cosentyx® (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumor necrosis factor (anti-TNF) therapy.
29 Sep 2015
Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Entresto™ (sacubitril valsartan). Pending final approval by the European Commission (EC), Entresto (sacubitril valsartan), previously known as LCZ696, will be licensed for use in the UK for the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction (HFrEF).
2 Sep 2015
Novartis today announced that its investigational heart failure treatment LCZ696 (sacubitril valsartan) has been given a positive scientific opinion under the Medicines and Healthcare products Regulatory Agency (MHRA) Early Access to Medicines Scheme (EAMS) for patients with significant unmet medical need. This allows LCZ696 (sacubitril valsartan) to be made available to eligible patients before a final European licensing decision is made.
Adverse event reporting
Product Information Leaflets (PILs) for patients
Summary of Product Characteristics (SPC) for Healthcare Professionals